{"id":"requip-pr","safety":{"commonSideEffects":[{"rate":"40-60","effect":"Nausea"},{"rate":"25-40","effect":"Dizziness"},{"rate":"20-40","effect":"Somnolence"},{"rate":"5-10","effect":"Hallucinations"},{"rate":"10-20","effect":"Orthostatic hypotension"},{"rate":"15-25","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL3314608","moleculeType":"Small molecule","molecularWeight":"691.87"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Requip (ropinirole) is a non-ergot dopamine agonist that preferentially binds to dopamine D2 and D3 receptors. The prolonged-release (PR) formulation provides sustained dopamine receptor stimulation over 24 hours. This mechanism helps restore dopamine signaling in the basal ganglia, which is deficient in Parkinson's disease.","oneSentence":"Requip PR is a dopamine agonist that stimulates dopamine receptors in the brain to increase dopamine activity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:31:49.007Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Parkinson's disease"},{"name":"Restless legs syndrome"}]},"trialDetails":[{"nctId":"NCT00434304","phase":"PHASE2","title":"Clinical Evaluation of Ropinirole PR/XR Tablets in Monotherapy for Parkinson's Disease (PD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-04-09","conditions":"Parkinson Disease","enrollment":62},{"nctId":"NCT01536574","phase":"PHASE3","title":"Open-Label Extension Study With REQUIP PR for Subjects From Study ROP111528","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-09-02","conditions":"Parkinson Disease","enrollment":295},{"nctId":"NCT01154166","phase":"PHASE3","title":"A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of Six Months Treatment With Ropinirole PR as Adjunctive Therapy in Patients With Parkinson's Disease Who Are Not Optimally Controlled on L-Dopa","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-02-15","conditions":"Parkinson Disease","enrollment":347},{"nctId":"NCT01485172","phase":"PHASE4","title":"A Fixed Dose, Dose Response Study for Ropinirole Prolonged Release in Patients With Early Stage Parkinson's Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-01-31","conditions":"Parkinson Disease","enrollment":186},{"nctId":"NCT01494532","phase":"PHASE4","title":"A Fixed Dose Study of Ropinirole Prolonged Release as Adjunctive Treatment in Patients With Advanced Parkinson's Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-04-02","conditions":"Parkinson Disease","enrollment":352},{"nctId":"NCT01435915","phase":"PHASE1","title":"Ropinirole PR Pharmacokinetics Study Among Chinese Healthy Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-06-28","conditions":"Parkinson Disease","enrollment":24},{"nctId":"NCT00331149","phase":"PHASE3","title":"A Comparison of Ropinirole Immediate Release With Ropinirole Prolonged Release in Patients With Advanced Parkinson's","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-06-20","conditions":"Parkinson Disease","enrollment":343},{"nctId":"NCT00823836","phase":"PHASE3","title":"Clinical Evaluation of Ropinirole Prolonged Release/Extended Release (PR/XR) Tablet for Adjunctive Therapy to L-dopa in Subjects With Advanced Parkinson's Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-03","conditions":"Parkinson Disease","enrollment":302},{"nctId":"NCT00460148","phase":"PHASE2","title":"Parkinson's Disease Patient Study On Absorption, Distribution, Metabolism And Excretion Of Ropinirole","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-04","conditions":"Parkinson Disease","enrollment":28},{"nctId":"NCT00986245","phase":"PHASE4","title":"Study to Compare the Effect of Ropinirole Prolonged Release Once-daily Versus Twice-daily","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2009-09","conditions":"Parkinson Disease","enrollment":82},{"nctId":"NCT00275275","phase":"PHASE3","title":"Pramipexole Conversion to Ropinirole Controlled Release (CR)","status":"COMPLETED","sponsor":"Rajesh Pahwa, MD","startDate":"2006-01","conditions":"Parkinson Disease","enrollment":61}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":23,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Requip 24-hour prolonged release (PR)."],"phase":"phase_3","status":"active","brandName":"Requip PR","genericName":"Requip PR","companyName":"Rajesh Pahwa, MD","companyId":"rajesh-pahwa-md","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Requip PR is a dopamine agonist that stimulates dopamine receptors in the brain to increase dopamine activity. Used for Parkinson's disease, Restless legs syndrome.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}